1. Home
  2. SSM vs SNGX Comparison

SSM vs SNGX Comparison

Compare SSM & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSM

Sono Group N.V. Ordinary Shares

N/A

Current Price

$6.90

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.22

Market Cap

12.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSM
SNGX
Founded
N/A
1987
Country
Germany
United States
Employees
43
16
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
12.3M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
SSM
SNGX
Price
$6.90
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.6K
110.0K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.34
$1.02
52 Week High
$10.47
$6.23

Technical Indicators

Market Signals
Indicator
SSM
SNGX
Relative Strength Index (RSI) 44.67 48.60
Support Level $6.70 $1.19
Resistance Level $7.00 $1.22
Average True Range (ATR) 0.13 0.07
MACD -0.04 0.01
Stochastic Oscillator 9.09 44.35

Price Performance

Historical Comparison
SSM
SNGX

About SSM Sono Group N.V. Ordinary Shares

Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: